Press Releases - Cardiol Therapeutics

Investor Resources

Contact Us

Investor ResourcesPress Releases

Press Releases

Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot

December 5, 2023

Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

November 16, 2023

Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis

November 1, 2023

Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

October 20, 2023

Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction

October 10, 2023

Cardiol Therapeutics to Present at Cantor Fitzgerald 2023 Global Healthcare Conference

September 26, 2023

Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx™ for the Treatment of Acute Myocarditis

September 19, 2023

Cardiol Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference

August 9, 2023

Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market

August 8, 2023